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Abstract- Tri-functional antibodies, as an effective novel tumor targeting agents, are composed of anti-CD3 
rat IgG2b and an anti-tumor antigen antibody. We have intended to develop a novel drug system to induce the 
apoptosis of HER2-expressing tumor cells, activate and engage cytotoxic T lymphocytes, natural killer cells, 
and macrophages. In addition, the drug can  inhibit programmed death ligand 1 (PDL-1)-expressing tumor 
cells. We have designed a mammalian vector system suitable to express the trifunctional antibody composed 
of antiHER2×human-CD80: human-IgG1Fc antibody. This antibody contains four chains of anti-HER2/CL, 
anti-HER2/CH1-3, B7.1/CL, and B7.1/CH1-3 within the human IgG1 framework and so the vector system will 
simultaneously express the four chains. The amino acid/nucleotide sequences datasets were retrieved from the 
GenBank, UniProtKB and PDB databases. The heavy and light chains variable domain framework regions 
and complementarity determining regions of scA21 antibody were determined by IMGT/V-QUEST and 
Paratome software. The amino acid sequences of tri-functional antibody chains manually were assembled and 
converted to DNA sequences by sequence manipulation suite software. The adapting codon usage of these 
DNA sequences was performed by JCAT software. Finally, the secondary structures of obtained RNAs from 
the DNAs were individually analyzed by RNAfold program. The Prodigy equilibrium dissociation constant, a 
ratio of koff/kon, between the antibody and its antigen for hantiHER2VHCH-HER2, hantiHER2VLCL-HER2, 
CD80CH-CD28, and CD80CL-CD28 were equal to 3.60E-10, 3.10E-9, 1.10E-8 and 2.70E-10; respectively. 
These findings were confirmed the composition and nano-molar affinity of the respective constructs. A single 
specific no-cloning expression vector, pHuchiTriomAb, was designed in silico with a desirable length of 
8.292 Kbps and bidirectional expression potential for the four chimeric antibody chains. This construct was 
designed, and gene codon usage adapted to be expressed within CHO cells and secreted a trifunctional 
antibody into the cell culture medium by interleukin 21 signal peptide.This robust expression system for rapid 
production of tri-functional antibody has been designed to substitute hybrid hybridoma technology (quadroma 
and trioma) with the facilitated purification of the trifunctional antibody from the antibody variants.  
© 2018 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran 2018;56(3):140-150. 
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Introduction 
 
Cancer is a complicated disease with many different 
types of assorted clinical therapeutics. Advances in 
cancer treatment are important in the detection of 
suitable targets for therapy. Developing targeted 
receptor tyrosine kinases is one of the most effective 
approaches for cancer treatment. These receptors play a 
significant role in the progression to aggressive tumor 
growth and poor prognosis. The human epidermal 
growth factor receptor (HER) family includes EGFR 
(HER 1 or ErbB-1), HER2/c-neu (ErbB-2), HER3 
(ErbB-3), and HER4 (ErbB-4) high-affinity receptor 
tyrosine kinases (1,2).  HER2 over-expression is 
involved in tumor proliferation, division, and 
angiogenesis, indicating neoplastic progression (3,4). 
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Some cancers such as breast, pancreatic, gastric, 
ovarian, and cholangiocarcinoma over-express the 
HER2 receptor. Thus, this receptor has been targeted for 
the eradication of tumor cells. ChA21 is an antibody to 
HER2; it binds to the extracellular subdomain-I of 
HER2 and efficiently induces apoptosis in ovarian 
carcinoma cells (SK-OV-3 cells). 
Tri-functional antibodies (TriomAb), which are 
effective-novel tumor targeting agents, are composed of 
anti-CD3 rat IgG2b and an anti-tumor antigen antibody. 
Drugs such as catumaxomab and ertumaxomab are 
effective at low doses, show higher efficacy than 
monoclonal antibodies, and have been shown to be 
effective in clinical phase III and II trials (5). 
Ertumaxomab targets HER2/neu, CD3, and FcrtypeI/III 
receptors to assemble a tri-cell complex in the tumor, T, 
and accessory cells. The anti-tumor efficacy of 
ertumaxomab against HER2/neu low-tumors which are 
resistant to Herceptin has been demonstrated previously 
(5). Similarly, Catumaxomab targets T-cell CD3, 
EpCAM tumor antigen, and accessory cells Fcγ I/III 
receptors and resembles ertumaxomab; however, it 
targets different tumor cells. Catumaxomab has been 
examined in phase III clinical trials (5). 
The B7.1 or CD80 costimulatory ligand is a member 
of the cell surface immunoglobulin superfamily and is 
expressed on the surface of antigen-presenting cells, 
including activated B cells, macrophages, and dendritic 
cells. Its dimers interact with T-cell CD28 and CTLA-4 
receptors in two separate pathways. The CD80/CD28 
pathway induces T-cell activation, cytokine production 
(i.e., IL-1, IL-2, IL-6, IL-12, TNF-α, IFN-γ), and 
cytotoxic T-lymphocyte (CTL) generation. The 
CD80/CTLA-4 pathway induces T-cell tolerance and 
immune response regulation. The CD80-Fc fusion protein 
may dramatically affect the proliferation and cytotoxicity 
of normal lymphocytes (6). In this regard, the tumor cells 
such as breast and ovarian cancers escape anti-tumor 
cellular immunity by expressing programmed death 
ligand-1 (PDL-1), which interacts with T-cell PD-1 to 
result in T-cell apoptosis. It contributes to tumor cell 
rescue from Fas ligand-mediated lysis, which may 
maintain tumor cells in situ (7). 
Although it has been proved that the triomabs are 
potent and effective therapeutic agents in cancer 
therapy, the design and production of these complex 
structures have been difficult. Since the function of 
triomabs depends on expression of the IgG chains for 
specific sites to target and initiate the cell death, design 
of a plasmid with proper cassettes is essential in 
antibody production. In this study, we have designed a 
single specific no-cloning expression vector in silico, 
pHuchiTriomAb, for the TriomAb, antiHER2×human-
B7.1:human-IgG1Fc antibody, which contains four 
chains of anti-HER2/CL, anti-HER2/CH1-3, B7.1/CL, 
and B7.1/CH1-3 within the human IgG1 framework. This 
antibody can induce the apoptosis of HER2-expressing 
tumor cells and activated cytotoxic T cells, natural killer 
cells, and macrophages as well as inhibiting the PDL-1-
expressing tumor cells.  
  
Materials and Methods 
 
GenBank, UniProtKB, and PDB databases  
The antibody experimental data sets of A4.6.1 
(anti-VEGF-A) scFv, Hu2.10 scFv (humanized anti-
VEGF), and Hu2.0 scFv were used. The data sets of 
cha21 antiHER2 (3H3B), scA21 antiHER2 (2GJJ), 
human B7.1 (1I8L), Newcastle disease virus (NDV) 
furin-cleavage (PIZA05N277, human IgG1 framework 
(1HZH-H&K), foot-mouth disease virus (FMDV) 2A 
peptide (P03305), EF1-HTLV promoter (KC176267), 
CMV-HTLV promoter (KCl76268), EM2KC promoter 
(AB902850), SV40-βglobin polyA (JO2400), Zeocin 
resistance sh-ble gene (EDN63766), ColE1 (JO1566), 
and pUC57 replication origin (γ14857) amino acid and 
nucleotide sequences were obtained from the GenBank, 
UniprotKB and PDB databases (Table 1, Suppl. Table 
1). 
 
 
Table 1. Retrieving affinity data of antibody-antigen and receptor-ligand 
Antibody/Receptor Antigen/Ligand kD(nM) 
A4.6.1scFv VEGF-A 1.6 
scA21scFv ErbB2 13.1 
Human B7.1(CD80) CD28 400 
CTLA-4 CD28 400 
The affinity of some antibody scFv forms and ligand to VEGF-A antigen and CD28 receptor has been represented, 
respectively. These affinities contributed us to compare them with bioinformatics outputs 
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IMGT/V-QUEST (ImMunoGeneTics) 
IMGT/V QUEST is an integrated system used for the 
standardized analysis of immunoglobulin (IG) 
rearranged nucleotide sequences. IMGT/V QUEST 
identifies frameworks (FRs) and complementarity 
determining regions (CDRs) of IG variable domains (8). 
Murine scA21 VH & VL and murine A4.6.1 VH & VL 
nucleotide sequences in FASTA format files were input 
into the IMGT/V-QUEST portal. 
 
Paratome 
The Paratome web server predicts the antigen-
binding regions (ABRs) of an antibody (Ab), given 
amino-acid sequences, or 3D structures corresponding to 
input file type, FASTA, or pdb. It exploits the consensus 
region dataset derived from the structural alignment of a 
non-redundant set of all known antibody-antigen 
complexes. The web server identifies the submitted 
antibody sequence or structure, which corresponds to the 
consensus ABRs. The paratome web server is available 
at http://www.ofranlab.org/paratome/(9). Murine scA21 
VH & VL (anti-HER2) and murine A4.6.1 (anti-VEGF) 
VH & VL amino acid sequence datasets (10, 11) in 
FASTA format were input into the paratome  portal.  
 
Chimeric and humanized dataset  
The required datasets for designing the chimeric 
protein framework consisted of a signal peptide 
(interleukin-21 signal peptide, Il-21 SP), HuscA21 
VHCH, Newcastle disease virus furin cleavage site, 
foot-mouth disease virus 2A peptide, HuscA21 VLCL, 
B7.1CH, and B7.1CL. 
 
SMS (Sequence manipulation suite): Reverse 
Translate  
SMS Reverse Translate accepts a protein sequence 
as input and uses a codon usage table to generate a DNA 
sequence, by representing the most likely non-
degenerate coding sequence. This program is available 
at www.bioinformatics.org/sms2/rev-trans.html.The two 
constructed chimeric protein frameworks above were 
converted to DNA frameworks using SMS: Reverse 
Translate. The input data sets were in FASTA format. 
 
FLAG and His tagging 
Two different tags were used, including a 3×FLAG 
tag and a His-3×FLAG tag. These were individually 
considered for designing gene cassettes. 
 
JCAT (Java codon adaptation tool)  
JCAT is an application for adapting target gene 
codon usage to most sequenced prokaryotes and selected 
eukaryotic gene expression. It is used to improve 
heterologous protein production. This application does 
not require the manual definition of highly expressed 
genes (10). The JCAT output is graphics and as codon 
adaptation index (CAI) values given for both the pre-
improved sequence and the improved sequence. JCAT is 
integrated into the PRODORIC database that hosts 
information for various organisms to fulfill the requested 
calculations. JCAT is accessible at 
http://www.prodoric.de/JCAT. The two obtained DNA 
frameworks were optimized using the JCAT tool based 
on codon bias of the considerable host cell (CHO cells). 
 
GeneScript rare codon analysis tool  
The two optimized DNA frameworks were evaluated 
using the GenScript rare codon analysis tool. It is 
accessible at www.genscript.com/cgi-bin/tools/rare-
codon-analysis. 
 
Sequence editor (DNA to RNA converter)  
Sequence editor accepts a nucleic acid sequence in 
FASTA format (without name). It converts DNA 
sequences into RNA sequences in FASTA format. It is 
accessible at www.fr33.net/seqedit.php.The two 
confirmed optimized DNA frameworks were converted 
to RNA using sequence editor. 
 
RNAfold program (Vienna RNA package)  
RNAfold is a program for predicting RNA secondary 
structure. The program uses only the default settings 
(11) and is available at http://rna.tbi.univie.ac.at/cgi-
bin/RNAfold.cgi. 
 
TriomAb expression vector datasets  
The required dataset including the CMV-HTLV 
promoter, two TriomAb gene cassettes, SV40 polyA, 
pUC57 ori, EF1-HTLV promoter, EM2CK promoter, and 
zeocin resistance gene (sh-ble gene) was applied to design 
a TriomAb expression vector (see Suppl. Table 1). 
 
SnapGene viewer 
The TriomAb expression vector features were 
highlighted, and the orientations were determined using 
SnapGene Viewer. The TriomAb expression vector was 
plotted using SnapGene viewer.  
 
Results 
 
FRs and CDRs discrimination 
The first step in manipulating FR regions of antibody 
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VH and VL is discriminating FRs and CDRs within the 
VH and VL amino acid sequences. Hence, we applied 
the IMGT-gap tool for discrimination. The system 
analyzed the sequences and displayed CDR and FR 
boundaries (see Suppl. Tables 2,3).  
 
ABRs determination 
The presence of the amino acid residues of ABRs for 
binding to the antigen is necessary. Therefore, the ABRs 
within the VH and VL amino acid sequences of scA21 
and A4.6.1 were predicted utilizing the Paratome tool. 
This was conducted to identify which amino acids must 
be restrained and which must be manipulated (see Suppl. 
Table 4). 
 
Multiple alignments and humanizing antibody  
In order to humanize the murine antiHER2VH and 
VL structures, it was required to retrieve the prevalent 
sequences of the VH and VL structures from humans. 
The VH-III and VL-I regions, are the most prevalent 
human antibody variable regions whose sequences were 
retrieved from the UniProtKB database. Next, these 
amino acid residue sequences with similar sequences to 
the murine antiHER2 VH and VL were aligned using the 
PRALINE multiple alignment web server. Two types of 
humanization were utilized; one based on bevacizumab 
human VH&VL-FRs and the other based on the 
prevalent VH-III&VL-I FRs. The exchangeable regions 
(FRs) determined in the initial section of the study were 
determined using the IMGT and Paratome servers. 
Bevacizumab human VH-FR1 
(EVQLVESGGGLVQPGGSLRLSCAASG), VH-FR2 
(WIRQAPGKGLE), VH-FR3 
(AADFKRRFTISLDTSASTVYLQMNSLRAEDTAVY
YCA), VH-FR4 (WGQGTLVTVSS), VL-FR1 
(DIQMTQSPSSLSASVGDRVTITCSAS), VL-FR2 
(WYQQKPGKAPK), VL-FR3 
(VPSRFSGSGSGTDYTLTISSLQPEDFATYYC), and 
VL-FR4 (TFGQGTKVEIK) were utilized for 
humanizing the constructs. Humanization of 
HuantiHER2scFvN2 was performed using the prevalent 
sequences of human VH-FRs and VL-FRs, including 
VH-FR1 (EVQLVESGGDLVKPGESLRLSCKAS), 
VH-FR2 (WVRKNTGKGLE), VH-FR3 
(NQKFKNRFTISRDDSKNTLYLQLNSLTSEDTAVY
YC), VH-FR4 (WGQGTTVTVSS), VL-FR1 
(DIQMTQSPSSLSVSVGDRVTITCRAS), VL-FR2 
(WYQQKPGQAPK), VL-FR3 
(GVPSRFSGSGSGTDFTLTISSLQPEDIATYYC), and 
VL-FR4 (TFGQGTKLEIKR).   
 
Inserting FLAG and His tags within gene cassettes 
An efficient method for purifying proteins is to 
utilize the peptide tags such as His tags. The purification 
tags of 3FLAG 
(DYKDHDGDYKDHDIDYKDDDDK) and 
9His3FLAG 
(HHHHHHHHHDYKDHDGDYKDHDIDYKDDDDK) 
were inserted at the N-terminus of antiHER2VLCL and 
B71.CL;respectively (Figure 1). The individual 
3FLAG tag was utilized for the antiHER2CHCHVLCL 
gene cassette. The chimeric 9His-3FLAG tag was 
utilized for the B7.1CHB7.1CL gene cassette. The tag 
peptide sequences were converted to nucleotide 
sequences according to the codon usage of CHO cells 
for gene cassettes. 
 
 
Figure 1. Tag locations. A: Blue region within the N-terminus of the 
HuantiHER2-VLCL model illustrates the 3FLAG tag. B: Blue and 
brown regions within the N-terminus of the B7.1CL model illustrate 
the 3FLAG and 9His tags; respectively. These models confirmed that 
the tags were exposed and detectable by relevant antibodies 
 
Conversion of protein primary structure to 
nucleotide primary structure  
The expression vector design of the primary 
structure of protein chains must be converted to primary 
nucleotide structures. This process was performed 
according to using standard codons in the SMS server. 
 
Optimization of gene cassettes 
It is necessary to optimize the expressing gene 
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cassettes according to the host cell, CHO cells, based on 
its codon usage to increase the probability of mRNA 
translation.  
The criteria values of the CAI and GC-content for 
HuantiHER2 VHCH-VLCL and B7.1CH-B7.1CL gene 
cassettes before optimization were 0.30–56.27 and 0.26–
53.2, respectively. The values of CAI and GC-content 
after optimization using the JCAT server were 0.71–
64.92 and 0.72–63.46; respectively. The value range of 
CAI is from 0.0 to 1.00. Greater CAI values near 1.00 
lead to more frequent codon usage in the considered 
sequence (Table 2). 
 
Evaluation of the optimized gene cassettes  
The optimized primary nucleotide structures were 
evaluated using the gene evaluation software in the 
GeneScript server to determine the quality of the 
structure. The relevant software assessed the 
improvement in the quality of HuantiHER2VHCH-
VLCL and B7.1CH-B7.1CL optimized gene cassettes by 
determining CAI, GC-content, and codon frequency 
distribution (CFD) criteria according to codon usage in 
the species Cricetulus griseus. The CAI value of ideal 
and good levels of the expressed sequence is equal to 
1.00 and more than 0.8, respectively. The percentage 
range of ideal GC-content is between 30% and 70%. 
Each peak out of the range negatively affects 
transcription and translation efficacy. The most frequent 
amino acid codon usage in a cassette-expressing 
organism has a CFD equal to 100%. In this study, the 
calculated values of CAI, GC-content, and CFD criteria 
for the HuantiHER2VHCH and B7.1CH-B7.1CL gene 
cassettes were 1.00, 63.51, and 100%, respectively (see 
Suppl. Table 5). Consequently, the quality of the gene 
cassettes for expressed in CHO cells according to codon 
usage bias of the host cell was confirmed. 
 
Table 2. DNA improvement 
 Before adaptation After adaptation ion 
Gene 
Cassettes 
CAI- 
Value 
GC-
Content Curve 
CAI- 
Value 
GC-
Content Curve 
HuAntiHER2 
VHCH-VLCL 0.3037 56.269 
 
0.7137 64.919 
HuB7.1CH-
B7.1CL 0.2872 53.207 
 
0.7211 63.459 
The DNAs ofHuantiHER2 VHCH-VLCL and B7.1CH-B7.1CL gene cassettes based on codon usage of Cricetulus griseus for CHO 
host cell were optimized for silico. The relevant outputs have been shown as CAI and GC-content. These optimized findings showed 
the desirable states. CAI: Codon Adaptation Index 
 
 
Conversion of DNAs to mRNAs and evaluation of 
secondary structure 
The primary structure of the gene cassettes was 
converted into RNA sequences, and the secondary 
structure of the RNAs was evaluated using RNA fold 
server. The ribosome binding site must be free to 
increase the expression potential in the host cell. The 
secondary structure analysis of HuantiHER2VHCH-
VLCL mRNA and B7.1CH-B7.1Cl mRNA using 
RNAfold represented the minimum free energy (MFE), 
frequency of MFE, ensemble diversity, and base pair 
probability in the ribosome binding site were (-94.3.63 
Kcal/mol, 0.00%, 642.23, and 0.0) and (-886.94 
Kcal/mol, 0.00%, 530.35, and 0.0), respectively. Most of 
the base pairs belonged to the mfe structure; however, 
these base pairs were in positions after 400 and after 
800, suggesting that the structures did not slow the 
codon translation process, particularly when the 
ribosome binding sites were free. The initial regions of 
the structures contained blue and near blue color 
spectrum, suggesting that the base pair probability in the 
regions was very low. The very low base-pair 
probabilities in the regions confirmed that the sections 
of the mRNAs were free for ribosome binding.The large 
negative MFEs were created by two long mRNA 
sequences. The resulting mountain plots showed three 
curves, confirming the above probabilities (Table 3). 
 
Designing and plotting of pHuchiTriomAb 
The composition of the HuantiHER2VHCH-VLCL 
gene cassette consisted of the hEF1α- HTLV promoter, 
the relevant gene, and SV40 polyadenylation (pAn). 
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The B7.1CH-B7.1CL gene cassette consisted of the 
reverse complement CMV-HTLV promoter, the 
reverse complement of the relevant gene, and 
sv40pAn. The reverse complement EM2KC promoter 
was considered to be the sh-ble gene. This expression 
vector consisted of four parts; part 1: 
HuantiHER2VHCH-VLCL, gene cassette, expressing 
antiHER2 heavy and light chains; part 2: B7.1CH—
B7.1CL gene cassette, expressing CD28 inducer 
integrated to human IgG1 heavy and light chains; part 
3: on pUC57, creating the potential for plasmid 
amplification in the bacterial cell; part 4:sh-ble gene 
cassette, creating the potential for zeocin resistance 
both in bacterial and eukaryotic cells. The 
pHuchiTriomAb expression vector was composed of 
8292 base pairs; a length of less than 10,000 base pairs 
prevents breakage in the structure. The vector was 
designed to express bidirectional antibody chains. Each 
gene cassette was designed to express two heavy and 
light chains of the relevant antibody. SnapGene defines 
and determines the relevant features within the FASTA 
nucleotide sequence by plotting the vector (Figure 2).  
 
 
Table 3. Thermodynamic ensemble prediction 
RNAs The optimal secondary structure in Dot-bracket notation 
MFE 
secondary 
structure 
MFE(kcal/mo
l)/Frequency 
of MFE (%) 
Base-pairing 
probability at 
ribosome 
binding Site 
Mountain Plot 
KOZAK-
Huanti-
HER2CH-
Huanti-
HER2CL 
RNA 
GCCGCCAGCAUGUACAGGAUGC
AGCUGCUGAGCUGCAUCGCCCU
GAGCCUGGCCCUGGUGACCAAC
AGCGAGGUGCAGCUGGUGGAGA
GCGGCGGCGGCCUGGUGCAGCC
CGGCGGCAGCCUGAGGCUGAGC
UGCGCCGCCAGCGGCUACAGCU
UCACCGGCUACUUCAUCAACUG
GAUCAGGCAGGCCCCCGGCAAG
GGCCUGGAGUGGAUCGGCCACA
UCAGCAGCAGC 
((((((.((.(((((((((...((((((((.(((((.((.(((((.((.
((((.((((((.(((...((.....)).((((((((.(((((((((((...
.(((((.....((((..((((((((((((((((((.......)))))).))
))))))..)))).(((.(((.....))).)))(((((((.......)))))
))((((((.....)))).))(((....)) 
 
 
-912.60/0.00 Very Weak 
 
 
KOZAK-
B7.1CH-
B7.1CL 
RNA 
GCCGCCAGCAUGUACAGGAUGC
AGCUGCUGAGCUGCAUCGCCCU
GAGCCUGGCCCUGGUGACCAAC
AGCGUGAUCCACGUGACCAAGG
AGGUGAAGGAGGUGGCCACCCU
GAGCUGCGGCCACAACGUGAGC
GUGGAGGAGCUGGCCCAGACCA
GGAUCUACUGGCAGAAGGAGAA
GAAGAUGGUGCUGACCAUGAUG
AGCGGCGACAUGAACAUCUGGC
CCGAGUACAAG 
(((((..(((.......(((((((((....))))))))).(((((.(((((
(((.(((...)))...(((((...)))))..((..((.(((((((..((((
((((((((.((((((((.(((...((..((.(((.((.((((((((((.(
(((((((.....((...(((....(((((((((.(((.(((.((((..((..
....))..)))))))............ 
 
-886.94/0.00 Very Weak 
 
The mRNAs ofoptimizedHuantiHER2 VHCH-VLCL and B7.1CH-B7.1CL gene-cassettes were evaluated by RNAfold web server. It has been shown that the 
base-pairing probability at ribosome binding site is very weak 
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Figure 2. HuChiTriomAb expression vector. The no-cloning specific 
expression vector with a length less than 10 kbp and bidirectional 
expression potential for humanized antiHER2×human-B7.1: human-
IgG1Fc tri-functional antibody with 94.3% human composition in 
silico was designed and then plotted using SnapGene software 
 
Discussion 
 
As novel therapeutics, tri-functional antibodies are of 
growing interest because they can be used to support and 
explore new mechanisms of actions for disease 
treatments. The tri-functional antibodies are of particular 
interest due to their resemblance to conventional hIgG1 
therapeutics. However, obtaining pure tri-functional 
antibody is challenging because of the complexities that 
arise from the co-expression of 2 pairs of heavy and 
light chains. Therefore, both designs of an effective 
therapeutic tri-functional antibody and an expression 
system contribute to the development of therapeutic 
antibody and efficient production methods. Here, for 
eliminating the problems of hybrid hybridoma 
technologies, we have been achieved to design an 
expression vector system without the need to cloning 
and completely specific for CHO host cell expressions. 
To confirm the success of engineering solutions, use of 
protein modeling, protein-protein docking and 
underestimating of antibody binding affinity to its 
antigen is critical. 
Tri-functional antibodies, which are effective novel 
tumor targeting agents, are composed of anti-CD3 rat 
IgG2b and anti-tumor antigen antibody. The first studies 
of tri-functional antibodies highlighted two major 
limitations including the difficulty of producing large, 
homogeneous batches, and the lack of efficacy of 
murine antibody fragments.  Human anti-mouse 
antibody (HAMA) responses were seen in most treated 
patients, which severely decreased the efficacy of the 
murine molecules and excluded the possibility of 
multiple administrations. 
Thus, we have designed a novel drug based on 
antibodies to induce the apoptosis of HER2-expressing 
tumor cells, activate cytotoxic T-cells, natural killer 
cells, and macrophages and inhibition of programmed 
death ligand 1 (PDL-1)-expressing tumor cells.  
Our design is a TriomAb containing the humanized 
antiHER2×human-B7.1: human-IgG1Fc tri-functional 
antibody with 94.3% human composition in silico.   
Based on benchmarking from the composition of the 
antibodies VH-III and VL-I, which are the most 
prevalent isoforms in the human body, substitution of 
human FR for murine FRs within the antiHER2scA21 
antibody VH and VL was performed.This generated 
humanized (65%; 83/126) VH domain and 71% 
(81/114), which lacked a significant difference between 
the murine and humanized structures versus H, 
indicating a significant difference. The z criterion for 
humanized murine VH was determined as follows,  
 
1. ݖ ൌ
ೣభ
೙భି
ೣమ
೙మ
ට௣ሺଵି௣ሻሺ భ೙భା
భ
೙భሻ
 (1) 
and 
 
2. ݌ ൌ ௫భା௫మ௡భା௡మ 
and the results were 11.1, which was greater than 
z0.975 = 1.96ሺݖଵ ൌ ߙ 2ൗ , ߙ ൌ 0.05ሻ. Therefore, the Ho 
hypothesis was rejected; however, the H1 hypothesis was 
accepted. Hence, there was a significant difference 
between the humanized and murine antiHER2VH 
structures.  
The z criterion for the humanized murine VL 
structure was 11.8, which is greater than z0.975 = 1.96 (z1-
α/2, α = 0.05). Thus, the Ho hypothesis was rejected 
while the H1 hypothesis was accepted. There was a 
significant difference between the humanized and 
murine antiHER2 VL structures.  
Prior to production, the quality of model structures 
should be calculated, and the interactions between 
protein-protein complexes should be analyzed based on 
rating scores for the efficient selection of structures. In 
addition, the protein models for integrating protein 
structures and building a single chimeric structure 
should be evaluated. This has been confirmed to 
determine the functional potential of protein structures 
not only in the chimeric state but also in the non-
chimeric state. 
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Different scoring schemes were used for the output 
values and for the experimental study values. The 
different scores for structural different features indicated 
direct and similar relationships in accordance with 
experimental outputs and confirmed that the 
effectiveness of this drug design route and its evaluation 
in efficiency and usability. 
This study contributes to the design TriomAbs and 
chimeric structures. In addition, there was overlap 
between the expected and observed results. Predicting 
the enhancement, reduction, and neutrality of chimeric 
structures from native functional or inducible structures 
and their affinities should be determined independently. 
This drug was designed to be exploited against cancer 
cells, HER2- and PDL-1-expressing cancer cells, such as 
breast and ovarian cancers. The Prodigy equilibrium 
dissociation constant, a ratio of koff/kon, between the 
antibody and its antigen (P-KD) for hantiHER2VHCH-
HER2, hantiHER2VLCL-HER2, CD80CH-CD28, and 
CD80CL-CD28 were equal to 3.60E-10, 3.10E-9, 
1.10E-8 and 2.70E-10; respectively. These findings were 
confirmed the composition and nano-molar binding 
affinity of the respective models. 
pHuchiTriomAb expression system possesses two 
robust eukaryotic promoters, hEF1α- HTLV and CMV- 
HTLV promoters, was designed to express two antibody 
mRNAs, including HuantiHER2VHCH1-3-
HuantiHER2VLCL and B7.1CH1-3-B7.1CL. Utilizing 
the contrived autocleavage-2A-peptide between 
HuantiHER2VHCH1-3 and HuantiHER2VLCL; and 
B7.1CH1-3 and B7.1CL antibody constructs contributed 
to the separation of the HuantiHER2VHCH1-3 and 
HuantiHER2VLCL, and B7.1CH1-3 and B7.1CL 
antibody construct from each other. The chains were 
assembled and secreted from CHO cells using the 
interleukin 21signal peptide. Also the purification tags 
of 3FLAGand 9His3FLAGwhich inserted at the N-
terminus of antiHER2VLCL and B71.CL;respectively, 
would contribute to two steps purification (Figure 1).At 
the first step, the variants of could be purified which 
possess 3FLAG at the N-terminus of antiHER2VLCL. 
At the second step, the variants of could be purified 
which possess both 3FLAG at the N-terminus of 
antiHER2VLCL and 9His3FLAG at the N-terminus of 
B71.CL.The individual 3FLAG tag was utilized for the 
antiHER2CHCHVLCL gene cassette. The attached tags 
are cleavable by enterokinase enzyme. This expression 
system was designed to eliminate the need for hybrid 
hybridoma (quadroma and trioma) technologies. 
In this study, four applications were successfully 
utilized. First, prediction of the antibody-antigen and 
ligand-receptor complex binding affinity in native and 
chimeric forms were determined by evaluating P-KD 
based on the experimental and in silico data. Second, a 
humanizing TriomAb with 94.3% human composition in 
silico was developed. Third, a desirable single specific 
no-cloning expression vector, pHuchiTriomAb, with a 
desirable length that of less than 10 Kbp and 
bidirectional expression potential for four different 
chimeric antibody chains was designed. This vector was 
designed to be expressed within CHO cells and secrete 
the antibody into the cell culture medium. Moreover, the 
vector contained two suitable tags for protein 
purification. Fourth, the design, modeling, binding 
potential estimation, and engineering of a TriomAb, 
HuantiHER2×human-B7.1: human-IgG1Fc antibody, 
which contained four chains of anti-HER2/CL, anti-
HER2/CH1-3, B7.1/CL, B7.1/CH1-3 within the human 
IgG1 framework were evaluated. This study is an in 
silico medel of vector to produce a triomab with equal 
production of antibodies to induce apoptosis in HER2-
expressing tumor cells as well as engaging cytotoxic T-
cells, natural killer cells, and macrophages in PDL-1-
expressing tumor cells. 
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Supplementary Table 1. Retrieving and Confirming Dataset. The obtained sequences from NCBI and 
UniProtKB were analyzed by using BLAST. This analysis confirmed the relevant sequence alignment. 
Max 
Score 
Total 
Score 
Query 
cover (%) 
E-
Value 
Identi
ty (%) Accession Entry UniprotKB PDB ID 
946 946 100 0.0 100 1 HZH-H IgG1 Po1857 1 HZH-H 
946 946 100 0.0 100 1 HZH-K IgG1 Po1834 1 HZH-K 
522 522 100 0.0 100 3H3B-D Cha21 - 3H3B 
539 539 100 0.0 100 2GJJ Sca21 - 2GJJ 
602 602 100 0.0 100 1I8L-B B7.1 P33681 1I8L-B 
4875 4875 100 0.0 100 P03305 FMDV-2Apeptide P03305 - 
11049 11049 100 0.0 100 Kc176267 EF1-HTLV Promoter - - 
12022 12022 100 0.0 100 Kc176268 CMV-HTLV Promoter - - 
13900 14032 100 0.0 100 AB902850 EM2KC - - 
9683 9951 100 0.0 100 Jo2400 SV40-Bglobin polyA - - 
503 503 100 8e-179 100 2WHU-D KRFP Q1JV70 2WHU-D 
496 496 100 4e-176 100 P42212 GFP P42212 1BFP 
212 212 100 2e-68 100 EDN63766 Zeocin Resistance Gene A6ZNA1 - 
264 264 100 3e-88 100 P0C2PO Blasticidin-S Resistance Gene deaminase POC2Po 1NN57 
12273 12273 100 0.0 100 JO1566 CoLE1 - - 
5005 5005 100 0.0 100 Y14837 PUC57 Replication Origin - - 
691 691 100 0.0 100 PIZA05N277 NDV - - 
 
 
 
 
Supplementary Table 2. VL-region IMGT analysis (ImMunoGeneTics). Annotation by IMGT/Automat 
(ImMunoGeneTics): After submitting nucleotide sequences of anti-HER2 Ab VL-region using IMGT 
tool, the data were analyzed, and the FRs& CDRs of the VL-region were identified. 
Label Location/Qualifiers
V-J-REGION IVLTQTPSSLPVSVGEKVTMTCKSSQTLLYSNNQKNYLAWYQQKPGQSPKLLISWAFTRK SGVPDRFTGSGSGTDFTLTIGSVKAEDLAVYYCQQYSNYPWTFGGGTRLEIK 
V-REGION 
allele="Musmus IGKV8-30*01 F", gene="Musmus IGKV8-30" 
IVLTQTPSSLPVSVGEKVTMTCKSSQTLLYSNNQKNYLAWYQQKPGQSPKLLISWAFTRK 
SGVPDRFTGSGSGTDFTLTIGSVKAEDLAVYYCQQYSN 
FR1-IMGT IVLTQTPSSLPVSVGEKVTMTCKSS 
CDR1-IMGT QTLLYSNNQKNY 
FR2-IMGT LAWYQQKPGQSPKLLIS 
CDR2-IMGT AA_IMGT:WAF 
FR3-IMGT TRKSGVPDRFTGSGSGTDFTLTIGSVKAEDLAVYYC 
CDR3-IMGT QQYSNYPWT 
FR4-IMGT FGGGTRLEIK 
 
 
 
 
Supplementary Table 3. VH-region IMGT analysis (ImMunoGeneTics). Annotation by IMGT/Automat: 
After submitting nucleotide sequences of anti-HER2 Ab VH-region using IMGT tool, the data were 
analyzed, and the FRs& CDRs of the VH-region were identified. 
Label Location/Qualifier
V-D-J-
REGION 
QQSGPEVVKTGASVKISCKASGYSFTGYFINWVKKNSGKSPEWIGHISSSYATSTYNQKF 
KNKAAFTVDTSSSTAFMQLNSLTSEDSAVYYCVRSGNYEEYAMDYWGQGTSVTVS 
V-REGION 
allele="Musmus IGHV1-39*01 F", gene="Musmus IGHV1-39" 
QQSGPEVVKTGASVKISCKASGYSFTGYFINWVKKNSGKSPEWIGHISSSYATSTYNQKF 
KNKAAFTVDTSSSTAFMQLNSLTSEDSAVYY 
FR1-IMGT QQSGPEVVKTGASVKISCKAS 
CDR1-IMGT GYSFTGYF 
FR2-IMGT INWVKKNSGKSPEWIGH 
CDR2-IMGT ISSSYATS 
FR3-IMGT TYNQKFKNKAAFTVDTSSSTAFMQLNSLTSEDSAVYYC 
CDR3-IMGT VRSGNYEEYAMDY 
FR4-IMGT WGQGTSVTVS 
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Supplementary Table 4. Paratome Analysis. The Ag-binding sites (ABRs) of antiHER2 Ab VL & VH 
regions were identified using Paratome tool 
ABR1 ABR2 ABR3 
QTLLYSNNQKNYLA LLISWAFTRKS QQYSNYPW 
>paratome_2_Anti_HER2_VH_CHs (heavy chain)  
QQSGPEVVKTGASVKISCKASGYSFTGYFINWVKKNSGKSPEWIGHISSSYATSTYNQKFKNKAAFTVDTSSSTAFMQLNSLTSEDS
AVYYCVRSGNYEEYAMDYWGQGTSVTVSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
NHYTQKSLSLSPGK 
ABR1 ABR2 ABR3 
YSFTGYFIN WIGHISSSYATSTY VRSGNYEEYAMDY 
 
 
 
 
Supplementary Table 5. Improved DNA Quality Evaluation.The DNAs of optimizedHuantiHER2 VHCH-
VLCL and B7.1CH-B7.1CL gene cassettes were evaluated by gene evaluation software of Genescript 
server. The output thereof as CAI, GC-content, and CFD were shown. It confirmed the desirable quality of 
DNA optimization 
Gene Cassettes Codon Adaptation Index (CAI) 
GC Content Adjustment 
GC curve 
Codon Frequency 
Distribution(CFD) 
HuAntiHER2 VHCH-
VLCL 
CAI:1.00 
 
 
 
 
Average GC content: 63.51 
 
 
 
 
 
CFD:100% 
HuB7.1CH-B7.1CL 
CAI:1.00 
 
 
 
 
Average GC content: 63.51 
 
 
 
 
CFD:100% 
 
